Skip to main content
Premium Trial:

Request an Annual Quote

Tata Consultancy Pens Protein Optimization Deal With Italian Biotech

NEW YORK, Aug. 4 (GenomeWeb News) - Tata Consultancy Services will provide its optimization tools to biotech start-up Congenia, the company said today.


Congenia, which is "promoted" by Italy's Genextra group, will use the technology to study P66, a target protein that Congenia believes is involved in several age-related diseases. The drug maker intends to develop optimized drug leads based on the protein.

TCS will use modules of its own product, TCS Bio-Suite, to work on the target protein. It will screen a "virtual fragment library" of tens of thousands of potential lead molecules to "predict which molecules might bind themselves to the target protein, thereby inhibiting its function," the company said.


TCS said it will also produce a "first-cut analysis" of the ADMET profile of the lead molecules.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.